In today’s disruptive health care environment, how will biotech transform?

The 33rd edition of EY’s Beyond Borders Biotechnology Report offers a chance to take stock of the US and European biotechnology (biotech) industry’s impressive performance during a period of intense global disruption. Despite recent market volatility, biotech remains in a position of strength: strong outlook for revenues; robust R&D investments; and a massive tide of investor dollars waiting for future deployment. However, the current post-pandemic landscape has created new challenges, including a shortfall of talent across healthcare, policymaker-driven shifts in supply chain expectations and drug pricing, as well as scaling commercial infrastructure and operating in a sustainable manner. We will explore all of these topics – and more – during our Beyond Borders panel at the 2023 BIO International Conference in Boston.